

Qrono Inc. to Present at Cooley's 2020 National Capital Call Event

Pittsburgh, Pa., May 4, 2020 – Cooley LLP, the nation's foremost venture capital law firm, has selected Qrono Inc. and sixteen other early stage companies to present at its [Digital Health & Life Sciences Capital Call](#) virtual event June 4th at 11:30am eastern time. Qrono Inc, a preclinical stage immunotherapy company, targets antigen presenting cells to improve cancer-specific T cell responses. Qrono will introduce its new immune checkpoint inhibitor program in a rapid-fire pitch followed by Q&A.

About Qrono Inc.

Qrono Inc. is a preclinical stage company that is applying expertise in immunoengineering and formulation science to change how key immune cells perceive cancer. Qrono's lead product candidate, QR213, is a nanoparticle mTOR checkpoint inhibitor that has been shown to increase antigen presentation in conjunction with immunogenic agents. Qrono is a privately held company headquartered in Pittsburgh, PA. Additional information regarding Qrono is available at www.qrono.com or by Sam Rothstein, CEO srothstein@qrono.com.